

Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On December 20, 2013, the Food and Drug Administration informed InVivo Therapeutics Holdings Corp. (the Company) that the Company should expect the agency s response to the Company s November 22, 2013 protocol amendments during the week of December 23, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVO THERAPEUTICS HOLDINGS CORP.

Date: December 20, 2013

By: /s/ Michael J. Astrue
Michael J. Astrue

Interim Chief Executive Officer